• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国治疗抵抗型重症肌无力患者的医疗资源利用情况。

Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.

机构信息

a Alexion Pharmaceuticals , Boston , MA , USA.

b Evidera , Hammersmith , UK.

出版信息

J Med Econ. 2019 Jul;22(7):691-697. doi: 10.1080/13696998.2019.1592180. Epub 2019 Mar 29.

DOI:10.1080/13696998.2019.1592180
PMID:30841772
Abstract

To examine healthcare resource utilization associated with refractory myasthenia gravis (MG) in England. This was a retrospective cohort study of linked data from the Clinical Practice Research Datalink and the Hospital Episode Statistics database collected between 1997 and 2016. Included patients were ≥18 years of age at the index MG diagnosis. Patients with refractory MG were identified using an algorithm based on treatments received. Healthcare resource utilization since the index date was compared between refractory and non-refractory cohorts. The study included 1149 patients with MG, of whom 66 (5.7%) were refractory. Sex and age at diagnosis did not significantly differ between the refractory and non-refractory cohorts. Rates of healthcare resource utilization per person-year were significantly higher ( < .05) for patients with refractory compared to non-refractory MG for GP visits, visits to other healthcare professionals, outpatient visits and inpatient hospitalization. Patients in the refractory cohort spent more total days hospitalized since the index visit than patients in the non-refractory cohort (median, 33 vs. 16 days [ < .0001]). The algorithm for identifying refractory patients did not include clinical criteria. Also, treatments administered in hospitals or by specialists were not available in the databases. Patients in England with refractory MG more often visit healthcare providers, are hospitalized and visit an emergency room than patients with non-refractory MG.

摘要

为了研究英国难治性重症肌无力(MG)相关的医疗资源利用情况。这是一项回顾性队列研究,使用了 1997 年至 2016 年期间临床实践研究数据链接和医院事件统计数据库中的相关数据。纳入标准为指数 MG 诊断时年龄≥18 岁的患者。难治性 MG 患者的确定是基于所接受的治疗方法的算法。比较了指数日期后难治性和非难治性队列之间的医疗资源利用情况。该研究纳入了 1149 名 MG 患者,其中 66 名(5.7%)为难治性。难治性和非难治性队列在性别和诊断时年龄方面没有显著差异。与非难治性 MG 相比,难治性 MG 患者的人均医疗资源利用率(就诊次数、其他医疗专业人员就诊次数、门诊就诊次数和住院治疗次数)明显更高( < .05)。难治性队列的患者自指数就诊以来的总住院天数比非难治性队列的患者多(中位数,33 天比 16 天 [ < .0001])。用于识别难治性患者的算法未包括临床标准。此外,医院或专家提供的治疗方法在数据库中不可用。与非难治性 MG 患者相比,英国难治性 MG 患者更频繁地就诊、住院和去急诊室。

相似文献

1
Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.英国治疗抵抗型重症肌无力患者的医疗资源利用情况。
J Med Econ. 2019 Jul;22(7):691-697. doi: 10.1080/13696998.2019.1592180. Epub 2019 Mar 29.
2
Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.美国全身性重症肌无力(MG)的经济负担,以及常见合并症和急性 MG 事件的影响。
Curr Med Res Opin. 2024 Jul;40(7):1145-1153. doi: 10.1080/03007995.2024.2353381. Epub 2024 May 24.
3
Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.在美国,对于 EGFR 突变阳性 NSCLC 患者,处方阿法替尼或厄洛替尼作为一线治疗药物的相关医疗资源利用和成本。
J Med Econ. 2020 Jan;23(1):48-53. doi: 10.1080/13696998.2019.1645681. Epub 2019 Aug 9.
4
Healthcare resource utilization and direct medical costs associated with index and recurrent infection: a real-world data analysis.与首发和复发感染相关的医疗资源利用和直接医疗成本:真实世界数据分析。
J Med Econ. 2020 Jun;23(6):603-609. doi: 10.1080/13696998.2020.1724117. Epub 2020 Feb 13.
5
Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States.美国商业保险患者冷凝集素病的医疗资源利用情况。
J Med Econ. 2020 Aug;23(8):902-907. doi: 10.1080/13696998.2020.1764006. Epub 2020 May 20.
6
Cost analysis of myasthenia gravis from a large U.S. insurance database.从美国大型保险数据库分析重症肌无力的成本。
Muscle Nerve. 2011 Dec;44(6):907-11. doi: 10.1002/mus.22212.
7
A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.一项回顾性分析,旨在估算与商业保险美国患者治疗抵抗性抑郁症相关的医疗资源利用和成本。
PLoS One. 2020 Sep 11;15(9):e0238843. doi: 10.1371/journal.pone.0238843. eCollection 2020.
8
Survival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study.难治性重症肌无力的生存、预后和临床特征:一项长达 15 年的全国性队列研究。
J Korean Med Sci. 2021 Oct 11;36(39):e242. doi: 10.3346/jkms.2021.36.e242.
9
Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: A retrospective primary care database study.英国神经源性膀胱患者的药物利用模式以及医疗资源利用和成本:一项回顾性初级保健数据库研究。
Neurourol Urodyn. 2019 Jun;38(5):1278-1289. doi: 10.1002/nau.23981. Epub 2019 Mar 28.
10
Burden of pulmonary arterial hypertension in England: retrospective HES database analysis.英国肺动脉高压负担:回顾性 HES 数据库分析。
Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995040. doi: 10.1177/1753466621995040.

引用本文的文献

1
Rituximab for myasthenia gravis.利妥昔单抗治疗重症肌无力
Cochrane Database Syst Rev. 2025 Jul 3;7(7):CD014574. doi: 10.1002/14651858.CD014574.pub2.
2
Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population-based registry study.丹麦、芬兰和瑞典重症肌无力的经济和社会负担:基于人群的登记研究。
Eur J Neurol. 2024 Dec;31(12):e16511. doi: 10.1111/ene.16511. Epub 2024 Oct 9.
3
Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
依库珠单抗和依氟鸟氨酸治疗抗乙酰胆碱受体抗体阳性全身型重症肌无力的成本效果分析。
J Manag Care Spec Pharm. 2024 Jun;30(6):517-527. doi: 10.18553/jmcp.2024.30.6.517.
4
A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England.一项关于英国重症肌无力患者特征、治疗模式及医疗资源利用情况的回顾性观察研究。
Ther Adv Neurol Disord. 2024 Apr 16;17:17562864241237495. doi: 10.1177/17562864241237495. eCollection 2024.
5
Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study.重症肌无力患者的长期医疗资源利用与成本:一项基于瑞典全国人口的研究
Neuroepidemiology. 2024;58(6):460-469. doi: 10.1159/000538640. Epub 2024 Apr 23.
6
Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey.欧洲医师和患者对重症肌无力的看法:一项真实世界的调查。
Orphanet J Rare Dis. 2023 Jun 29;18(1):169. doi: 10.1186/s13023-023-02727-0.
7
Analysis of length of stay and treatment emergent complications in hospitalized myasthenia gravis patients with exacerbation.住院重症肌无力恶化患者的住院时间和治疗急症并发症分析。
BMC Neurol. 2023 Jan 12;23(1):12. doi: 10.1186/s12883-022-02922-9.
8
A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis.一项重症肌无力临床负担的回顾性纵向队列研究。
BMC Neurol. 2022 May 9;22(1):172. doi: 10.1186/s12883-022-02692-4.
9
Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States.美国难治性和非难治性全身性重症肌无力疾病负担的纵向分析。
J Clin Neuromuscul Dis. 2020 Sep;22(1):11-21. doi: 10.1097/CND.0000000000000301.
10
Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.近期接受慢性静脉注射免疫球蛋白治疗的重症肌无力患者对依库珠单抗的反应:REGAIN及其开放标签扩展研究的亚组分析
Ther Adv Neurol Disord. 2020 May 6;13:1756286420911784. doi: 10.1177/1756286420911784. eCollection 2020.